BONESUPPORT Signs Strategic Agreement with MTF Biologics

By Julie A. Vetalice

BONESUPPORT signed an agreement with MTF Biologics, gaining U.S. rights to demineralized bone matrices that complement CERAMENT bone void filler and Collagen Matrix bone graft substitute products.

BONESUPPORT will sell the MTF products under its own brand and through its own U.S. distribution network.

In May 2018, BONESUPPORT announced its intent to shift to direct U.S. sales and plan develop partnerships to help round out its suite of offerings. Subsequently, they signed an agreement with Collagen Matrix later that month.

BONESUPPORT's U.S. distribution channel is on track be in place in 4Q18.


Product Labels: Synthetic Bone Graft

Tags: M&A